Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medicines.